Catherine Diefenbach

5.6k total citations · 1 hit paper
160 papers, 2.2k citations indexed

About

Catherine Diefenbach is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Catherine Diefenbach has authored 160 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Pathology and Forensic Medicine, 70 papers in Oncology and 40 papers in Genetics. Recurrent topics in Catherine Diefenbach's work include Lymphoma Diagnosis and Treatment (90 papers), Chronic Lymphocytic Leukemia Research (40 papers) and CAR-T cell therapy research (38 papers). Catherine Diefenbach is often cited by papers focused on Lymphoma Diagnosis and Treatment (90 papers), Chronic Lymphocytic Leukemia Research (40 papers) and CAR-T cell therapy research (38 papers). Catherine Diefenbach collaborates with scholars based in United States, Germany and Canada. Catherine Diefenbach's co-authors include Ranjana H. Advani, Jeffrey M. Spivak, Owen A. O’Connor, Brad S. Kahl, Stephen M. Ansell, Nancy L. Bartlett, W. Buzello, Fangxin Hong, Hermann Mellinghoff and Jonathon B. Cohen and has published in prestigious journals such as Nature, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Catherine Diefenbach

149 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial

2025 42 citations Armin Ghobadi, Veronika Bachanová et al. The Lancet profile →

Peers

Countries citing papers authored by Catherine Diefenbach

Since Specialization

Citations

This map shows the geographic impact of Catherine Diefenbach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Diefenbach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Diefenbach more than expected).

Fields of papers citing papers by Catherine Diefenbach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Diefenbach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Diefenbach. The network helps show where Catherine Diefenbach may publish in the future.

Co-authorship network of co-authors of Catherine Diefenbach

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Diefenbach. A scholar is included among the top collaborators of Catherine Diefenbach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Diefenbach. Catherine Diefenbach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma 2025 ·Blood Advances ·Sairah Ahmed, John F. DiPersio, James Essell, Catherine Diefenbach, Miguel‐Angel Perales, Cristina Castilla‐Llorente, Saurabh Dahiya, (unknown), (unknown), Christie Fanton, Sohail S. Chaudhry, Zachary Lee, (unknown), Mary Tagliaferri, Jonathan Zalevsky, David B. Miklos, Cameron J. Turtle, Joseph P. McGuirk	1
2	NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL) 2025 ·Transplantation and Cellular Therapy ·Sairah Ahmed, John F. DiPersio, James Essell, Catherine Diefenbach, Miguel‐Angel Perales, C. Llorente, Saurabh Dahiya, (unknown), Christie Fanton, Sohail S. Chaudhry, Zachary Lee, (unknown), (unknown), Jonathan Zalevsky, David B. Miklos, Cameron J. Turtle, Joseph P. McGuirk	1
3	Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial breakdown → 2025 ·The Lancet ·Armin Ghobadi, Veronika Bachanová, Krish Patel, Jae H. Park, Ian W. Flinn, Peter A. Riedell, Carlos Bachier, Catherine Diefenbach, Carol Wong, (unknown), Lilly Wong, Deepa Patel, Jode Goodridge, (unknown), Bahram Valamehr, Rebecca Elstrom, Paolo Strati	42
4	Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study 2024 ·Blood ·Jacqueline Wang, Jihao Zhou, (unknown), Han W. Tun, Javier Muñoz, Jonas Paludo, Muhamad Alhaj Moustafa, Steven R. Hwang, (unknown), Catherine Diefenbach, Jia Ruan, Peter Martin, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Yucai Wang	0
5	Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study 2024 ·Journal of Clinical Oncology ·Lihua E. Budde, Sarit Assouline, Laurie H. Sehn, Stephen J. Schuster, Sung‐Soo Yoon, Dok Hyun Yoon, Matthew J. Matasar, Francesc Bosch, Won Seog Kim, Loretta J. Nastoupil, Ian W. Flinn, Mazyar Shadman, Catherine Diefenbach, Chan Y. Cheah, (unknown), Huang Huang, Antonia Kwan, Michael C. Wei, Shen Yin, Nancy L. Bartlett	34
6	Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL). 2024 ·Journal of Clinical Oncology ·Sarit Assouline, Lihua E. Budde, Julio C. Chávez, Catherine Diefenbach, Kathleen Dorritie, Nilanjan Ghosh, Adam J. Olszewski, Izidore S. Lossos, Amitkumar Mehta, Dipenkumar Modi, Seema Naik, Stephen D. Smith, (unknown), (unknown), Hao Wu, Connie Lee Batlevi, Iris To, Michael C. Wei, Manali Kamdar	0
7	Mosunetuzumab With Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL) 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Sarit Assouline, Lihua E. Budde, Julio C. Chávez, Catherine Diefenbach, Kathleen Dorritie, Nilanjan Ghosh, Adam J. Olszewski, Izidore S. Lossos, Amitkumar Mehta, Dipenkumar Modi, Seema Naik, Stephen D. Smith, (unknown), (unknown), Hao Wu, Connie Lee Batlevi, Iris To, Michael C. Wei, Manali Kamdar	1
8	terraFlow, a high-parameter analysis tool, reveals T cell exhaustion and dysfunctional cytokine production in classical Hodgkin’s lymphoma 2024 ·Cell Reports ·Daniel J. Freeman, Catherine Diefenbach, Linda Lam, Tri D. Le, (unknown), Bruce G. Raphael, Michael L. Grossbard, David Kaminetzky, Jia Ruan, Pratip K. Chattopadhyay	3
9	NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL) 2024 ·Blood ·Sairah Ahmed, John F. DiPersio, James Essell, Catherine Diefenbach, Miguel‐Angel Perales, Cristina Castilla‐Llorente, Saurabh Dahiya, Sohail S. Chaudhry, (unknown), (unknown), Christie Fanton, Zachary Lee, (unknown), Mary Tagliaferri, Jonathan Zalevsky, David B. Miklos, Cameron J. Turtle, Joseph P. McGuirk	0
10	Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Matthew J. Matasar, Nancy L. Bartlett, Mazyar Shadman, Lihua E. Budde, Ian W. Flinn, Gareth P. Gregory, Won Seog Kim, Georg Heß, Dima El‐Sharkawi, Catherine Diefenbach, Huang Huang, Iris To, (unknown), (unknown), Antonia Kwan, Sarit Assouline	10
11	Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study 2022 ·Clinical Cancer Research ·Alex F. Herrera, Manish R. Patel, John M. Burke, Ranjana H. Advani, Bruce D. Cheson, Jeff P. Sharman, Elicia Penuel, Andrew G. Polson, Chen Di Liao, Chunze Li, (unknown), Anjali Vaze, Divya Samineni, Rebecca Elstrom, James Cooper, Catherine Diefenbach	21
12	A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies 2021 ·Blood ·Elizabeth Budde, Ajay K. Gopal, Won Seog Kim, Ian W. Flinn, Chan Y. Cheah, Loretta J. Nastoupil, Matthew J. Matasar, Catherine Diefenbach, Gareth P. Gregory, (unknown), (unknown), Maya K. Leabman, Genevive Hernandez, (unknown), Bruce A. Keyt, Daniel Chen, Philippe Armand	22
13	Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial 2020 ·The Lancet Haematology ·Catherine Diefenbach, Fangxin Hong, Richard F. Ambinder, Jonathon B. Cohen, Michael J. Robertson, Kevin A. David, Ranjana H. Advani, Timothy S. Fenske, Stefan K. Barta, Neil Palmisiano, Jakub Svoboda, David Morgan, Reem Karmali, Elad Sharon, Howard Streicher, Brad S. Kahl, Stephen M. Ansell	97
14	Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial 2020 ·The Lancet Haematology ·Bruce D. Cheson, Nancy L. Bartlett, Betsy LaPlant, Hun Ju Lee, Ranjana H. Advani, Beth Christian, Catherine Diefenbach, Tatyana Feldman, Stephen M. Ansell	66
15	Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study 2019 ·Blood ·Anas Younes, John M. Burke, Bruce D. Cheson, Catherine Diefenbach, Silvia Ferrari, Uwe Hahn, Eliza A. Hawkes, Cyrus Khan, Izidore S. Lossos, Gerardo Musuraca, Monica Tani, Umberto Vitolo, (unknown), Aparna Raval, Mahesh Shivhare, Tina Nielsen, Gila Sellam, Jeff P. Sharman	20
16	Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma 2015 ·Clinical Cancer Research ·Jatin J. Shah, Andrzej Jakubowiak, Owen A. O’Connor, Robert Z. Orlowski, R. Donald Harvey, Mitchell R. Smith, Daniel Lebovic, Catherine Diefenbach, Kevin R. Kelly, Zhaowei Hua, Allison Berger, George Mulligan, Hélène M. Faessel, Stephen Tirrell, Bruce J. Dezube, Sagar Lonial	162
17	Diets Containing Pistachios Reduce Systolic Blood Pressure and Peripheral Vascular Responses to Stress in Adults With Dyslipidemia 2012 ·Hypertension ·Sheila G. West, Sarah K Gebauer, Colin D. Kay, Deborah M Bagshaw, David M. Savastano, Catherine Diefenbach, Penny M. Kris‐Etherton	46
18	Comparison of continuous epidural infusion of ropivacaine and sufentanil with intravenous patient‐controlled analgesia after total hip replacement 2001 ·Anaesthesia ·Sandra Kampe, (unknown), Peter Kiencke, (unknown), (unknown), (unknown), Catherine Diefenbach	32
19	Zuverlässigkeit und Dosisabhängigkeit des Train-of-Four count 1999 ·Der Anaesthesist ·Jens Krombach, Noel R. Krieg, Catherine Diefenbach	2
20	Validation of World Health Organization guidelines for pain relief in head and neck cancer. A prospective study. 1994 ·Rehabilitation Oncology ·Stefan Grond, D. Zech, John Lynch, Catherine Diefenbach, Stephan A. Schug, (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact